People with multiple sclerosis (MS) face a wide variety of physical, emotional, and social challenges. A multidisciplinary comprehensive care approach is recommended for the management of MS and its consequences, and non-traditional treatments are increasingly considered by patients and health care providers, particularly for the promotion of wellness in the context of this chronic disease. Previous research has demonstrated the benefits of the therapeutic arts (art therapy, dance and movement therapy, and music therapy) in addressing some of the physiological, psychological, cognitive, social, and spiritual needs of patients facing a variety of chronic illnesses. Our review of the literature suggests that therapeutic art can be beneficial to individuals with MS, particularly in promoting self-efficacy, emotional well-being, and motor control. However, the body of evidence is limited, and further research is needed regarding the outcomes and mechanism of action of therapeutic arts in MS to better understand their role in the management of the consequences of the disease.
Music therapy, art therapy, dance therapy, multiple sclerosis
Lisa Gallagher and Francois Bethoux have nothing to disclose in relation to this article. No funding was received in the publication of this article.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Lisa M Gallagher, Cleveland Clinic Arts & Medicine Institute, 1950 Richmond Rd/TR308, Lyndhurst, OH 44124, US. E: email@example.com
This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.
Share this Article
Related Content In Multiple Sclerosis
Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis
US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99
Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]
Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
European Neurological Review. 2020;15(1):27-35 DOI: https://doi.org/10.17925/ENR.2020.15.1.27
Multiple sclerosis (MS) has traditionally been considered a primarily T-cell-mediated autoimmune disease of the central nervous system (CNS); this is based on data from animal models,1 the presence of activated T lymphocytes in MS plaques that outnumber B cells and T-cell subset alterations in blood,2 the association of MS with certain human leukocyte antigen (HLA) and a […]
Ozanimod in Multiple Sclerosis
European Neurological Review. 2019;14(2):73–9
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system affecting almost 3 million individuals worldwide.1–3 The precise pathogenesis of the disease is unknown, though migration of peripheral T and B lymphocytes into the central nervous system is considered to be one of the major pathophysiologic mechanisms.4–6 Sphingosine-1-phosphate (S1P) modulators, through induction of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!